Alzheimer's drug prescribed off-label could pose risk for some

No Comment 0 View

Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test. Researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitive decline.



Source link

In : Health

About the author

Leave a Reply

Your email address will not be published. Required fields are marked (required)